The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries

Author:

Sicuri Elisa12,Yaya Bocoum Fadima3,Nonvignon Justice4,Alonso Sergi156,Fakih Bakar7,Bonsu George8,Kariuki Simon9,Leeuwenkamp Oscar10,Munguambe Khatia511,Mrisho Mwifadhi7,Were Vincent9,Sauboin Christophe12ORCID

Affiliation:

1. ISGlobal, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain

2. Health Economics Group, School of Public Health, Imperial College London, London, UK

3. Institut Free Afrik, Ouagadougou, Burkina Faso

4. School of Public Health, University of Ghana, Accra, Ghana

5. Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique

6. Centre for Primary Care and Public Health, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

7. Ifakara Health Institute (IHI), Dar es Salaam, Tanzania

8. Expanded Programme on Immunization, Ghana Health Service, Accra, Ghana

9. Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya

10. Eclipse, Tervuren, Belgium

11. Faculty of Medicine, Eduardo Mondlane University (UEM), Maputo, Mozambique

12. GSK, Wavre, Belgium

Abstract

Background. The World Health Organization has recommended pilot implementation of a candidate vaccine against malaria (RTS,S/AS01) in selected sub-Saharan African countries. This exploratory study aimed to estimate the costs of implementing RTS,S in Burkina Faso, Ghana, Kenya, Mozambique, and Tanzania. Methods. Key informants of the expanded program on immunization at all levels in each country were interviewed on the resources required for implementing RTS,S for routine vaccination. Unit prices were derived from the same sources or from international price lists. Incremental costs in 2015 US dollars were aggregated per fully vaccinated child (FVC). It was assumed the four vaccine doses were either all delivered at health facilities or the fourth dose was delivered in an outreach setting. Results. The costs per FVC ranged from US$25 (Burkina Faso) to US$37 (Kenya) assuming a vaccine price of US$5 per dose. Across countries, recurrent costs represented the largest share dominated by vaccines (including wastage) and supply costs. Non-recurrent costs varied substantially across countries, mainly because of differences in needs for hiring personnel, in wages, in cold-room space, and equipment. Recent vaccine introductions in the countries may have had an impact on resource availability for a new vaccine implementation. Delivering the fourth dose in outreach settings raised the costs, mostly fuel, per FVC by less than US$1 regardless of the country. Conclusions. This study provides relevant information for donors and decision makers about the cost of implementing RTS,S. Variations within and across countries are important and the unknown future price per dose and wastage rate for this candidate vaccine adds substantially to the uncertainty about the actual costs of implementation.

Funder

glaxosmithkline

Publisher

SAGE Publications

Subject

Public Health, Environmental and Occupational Health,Health Policy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3